AstraZeneca Aktie
WKN: 886715 / ISIN: US0463531089
03.10.2023 08:22:45
|
AstraZeneca Settles Nexium, Prilosec Product Liability Litigations; To Pay $425 Mln
(RTTNews) - British drug major AstraZeneca Plc (AZN.L, AZN) announced Tuesday that it has entered into settlement agreements in the product liability litigations related to Nexium and Prilosec. The specific terms of the agreements are confidential.
AstraZeneca agreed to make payment of $425 million, for which a provision has been taken.
Nexium and Prilosec are prescription only drugs used to treat patients with acid-related symptoms and diseases.
The company noted that the agreements effectively resolve the product liability claims that are currently pending in the Multidistrict Litigation in the US District Court for the District of New Jersey, as well as in the Delaware Superior Court and the New Jersey Superior Court.
AstraZeneca said it continues to believe these claims are without merit and admits no wrongdoing in the settlement agreement, but the settlements are reached to avoid continued costly litigation.
The company noted that the settlements allow it to move forward with its purpose of delivering life changing medicines.
A single case remains pending in the US District Court for the Middle District of Louisiana. In that case, trial is scheduled for April 15, 2024.
For More Such Health News, visit rttnews.com

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu AstraZeneca PLC (spons. ADRs)mehr Nachrichten
17.07.25 |
Aufschläge in New York: Gewinne im NASDAQ 100 (finanzen.at) | |
17.07.25 |
Aufschläge in New York: NASDAQ 100 zeigt sich am Mittag fester (finanzen.at) | |
16.07.25 |
AstraZeneca-Aktie im Minus: Anselamimab hat Studienziel nicht erreicht (Dow Jones) | |
14.07.25 |
Erste Schätzungen: AstraZeneca gibt Ergebnis zum abgelaufenen Quartal bekannt (finanzen.net) | |
04.07.25 |
AstraZeneca-Aktie höher: Summit Therapeutics und AstraZeneca sprechen über Ivonescimab-Deal (Dow Jones) | |
03.07.25 |
NASDAQ-Handel: NASDAQ 100 verbucht zum Handelsende Gewinne (finanzen.at) | |
03.07.25 |
Freundlicher Handel in New York: NASDAQ 100-Anleger greifen nachmittags zu (finanzen.at) | |
03.07.25 |
Starker Wochentag in New York: Anleger lassen NASDAQ 100 am Donnerstagmittag steigen (finanzen.at) |
Analysen zu AstraZeneca PLC (spons. ADRs)mehr Analysen
Aktien in diesem Artikel
AstraZeneca PLC (spons. ADRs) | 61,50 | 3,36% |
|